Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | UBE2M | P61081 | 2/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 5/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251803 | 0.93 | DRD2 (0.33) | DRD2ADRA1AUBE2MDCUN1D1THRB | |
| SCHEMBL2252142 | 0.93 | CCR5 (0.35) | DRD2ADRA1AUBE2MDCUN1D1TRPV1 | |
| SCHEMBL2254899 | 0.92 | CDK1 (0.35) | DRD2ADRA1AUBE2MDCUN1D1TRPV1 | |
| SCHEMBL2250451 | 0.92 | GPR119 (0.34) | DRD2ADRA1AUBE2MDCUN1D1TRPV1 | |
| SCHEMBL2253272 | 0.91 | UBE2M (0.36) | DRD2ADRA1AUBE2MDCUN1D1TRPV1 | |
| SCHEMBL2253967 | 0.90 | UBE2M (0.36) | DRD2ADRA1AUBE2MDCUN1D1TRPV1 | |
| SCHEMBL2249707 | 0.87 | UBE2M (0.32) | DRD2ADRA1AUBE2MDCUN1D1CDK1 | |
| SCHEMBL2250463 | 0.85 | CCR5 (0.35) | DRD2ADRA1AUBE2MDCUN1D1THRB | |
| SCHEMBL2250434 | 0.84 | CDK2 (0.36) | UBE2MDCUN1D1TRPV1THRBSCN9A | |
| SCHEMBL2253313 | 0.84 | CCR5 (0.36) | UBE2MDCUN1D1THRBCDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | claimed |
| US-8003642-B2 | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-08-23 | — | — | US | disclosed |
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-1995246-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131403-A1 | NITROGENATED HETEROCYCLIC DERIVATIVE , AND PHARMACEUTICAL AGENT COMPRISING THE DERIVATIVE AS ACTIVE INGREDIENT | CXCR3, CCR5, HLA-DRB1 | DRD2 2098/4885ADRA1A 702/4885UBE2M 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.